News
The day at a glance · 3 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
Pfizer Q1 Earnings
$2.69 billion
Big Pharma & Biotech
Omvoh 4-Year Clearance
60%
Big Pharma & Biotech
Intuitive Surgical Revenue Growth
10%+10%
MedTech & Devices
Key driverStrong pharmaceutical earnings momentum and breakthrough surgical robotics data offset by persistent insurance coverage gaps in specialty therapies
Daily briefHealthcare· Money365.Market AI ·

Pfizer Earnings Beat, J&J Robotics Data, UNH Eases Access

Big Pharma delivers Q1 results while medical device innovation advances and managed care reforms take hold

Big Pharma & Biotech

Bullish
PFEREGNLLY
Pfizer ($PFE) reported first-quarter profit above Wall Street estimates, driven by sustained demand for older drugs including blood thinner Eliquis and cancer drug Padcev. The company posted earnings of $2.69 billion with profit of 47 cents per share for the quarter. Meanwhile, Regeneron ($REGN) announced Phase 4 trial results showing Dupixent demonstrated significant and clinically meaningful improvements in esophageal distensibility as well as disease-related structural changes and inflammation in adult patients with eosinophilic esophagitis.
Eli Lilly ($LLY) reported durable long-term outcomes for Omvoh in ulcerative colitis, with the LUCENT-3 study showing more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous treatment.

MedTech & Devices

Bullish

Stryker Revenue Growth

567%+567%
JNJISRG
Johnson & Johnson ($JNJ) announced pivotal clinical study results for its investigational OTTAVA Robotic Surgical System, representing a critical milestone for the new soft-tissue surgical robotic platform. The data demonstrates feasibility of a novel system architecture with table-integrated robotic arms, positioning $JNJ to compete in the surgical robotics market. Separately, $JNJ received FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study for head and neck cancer, with the amendment eliminating previously planned requirements. The surgical robotics sector continues to see growth, with revenue from Intuitive Surgical ($ISRG) and Stryker increasing 10% and 567% respectively at key supplier UFP Tech.

Health Insurance & Managed Care

Bullish

Prior Auth Reduction

30%

Q1 Revenue

$111.72 billion

Q1 Net Income

$6.28 billion
UNH
UnitedHealth Group ($UNH) announced its insurance unit will eliminate prior authorization requirements for 30% of healthcare services, further reducing delays and paperwork for patients and doctors. The initiative builds on recently announced programs to reduce requirements for rural care providers and to standardize submission requirements among insurers.
$UNH reported first-quarter revenue of $111.72 billion and net income of $6.28 billion in April, while simultaneously facing a shareholder proposal from The Accountability Board to require an independent Board Chair. The company's proxy statement urged investors to vote against the governance proposal.

Drug Access & Pricing

Neutral
GILD
Gilead Sciences ($GILD) reported rising use of its twice-yearly HIV prevention injection Yeztugo since its June launch, though U.S. health providers indicate not all patients are interested in the new option. Insurance gaps remain a significant challenge to broader adoption of the injectable PrEP therapy. The mixed uptake highlights ongoing challenges in translating innovative therapies into widespread clinical use, particularly when insurance coverage remains inconsistent across payer networks.

Looking Ahead

Bullish

LLY DCF Fair Value Range

$956-$960

DNA/RNA Sequencing 2026 Market

$10.2 billion

DNA/RNA Sequencing CAGR

18.5%
LLYJNJTMO
The healthcare sector faces multiple catalysts in coming weeks including continued GLP-1 competition between Eli Lilly ($LLY) and Novo Nordisk, with analyst DCF fair value estimates for $LLY ranging from $956 to $960. Progress on Johnson & Johnson's ($JNJ) OTTAVA robotic system commercialization timeline will be closely watched as the company advances toward regulatory submissions. The targeted DNA/RNA sequencing market is projected to expand significantly, with market research forecasting growth from $8.6 billion in 2025 to $10.2 billion in 2026 and reaching $46.9 billion by 2035 at an 18.5% CAGR, benefiting key players including Thermo Fisher Scientific ($TMO) and Illumina.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy